New York Blood Center
The center announced that it has received a patent for chemical process which inactivates hepatitis and HTLV-III viruses in blood protein derivatives "without affecting the functioning of the proteins in the coagulation factor concentrates or the activity of other blood proteins." The process destroys the viruses by disrupting the lipid containing envelope surrounding hepatitis and HTLV-II viruses which is necessary for the viruses to bind to and infect cells.
You may also be interested in...
Amwell’s increased the size of its IPO and raised $742m when it sold 41.2 million shares at $18 each.
Pink Sheet Podcast: COVID-19 Stresses Manufacturing, Vaccine Placebo Controls, Thorny FDA Precedents
Pink Sheet reporters and editor discuss the pandemic’s effects on non-coronavirus-related product manufacturing, US FDA efforts to ensure vaccine sponsors maintain placebo controls once a product is available, and precedents that burden the agency.
While Accord HealthCare has convinced the European Medicines Agency that its rivaroxaban generic should be approved in the EU, Bayer has warned that patent protection for Xarelto continues until at least late 2023. The EMA this week also recommend approval for a number of other new drugs.